Open AccessEffect of Alternate Treatment with Intravitreal Corticosteroid and Anti-VEGF for Macular Edema Secondary to Retinal Vein Occlusion
Author(s) -
Young Hwan Bae,
Seong Mi Kim,
Jin Young Kim,
So Hyun Bae,
Hakyoung Kim,
Dae Joong
Publication year - 2021
Publication title -
journal of ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.818
H-Index - 40
eISSN - 2090-0058
pISSN - 2090-004X
DOI - 10.1155/2021/5948113
Subject(s) - medicine , macular edema , visual acuity , retinal vein , ophthalmology , pro re nata , occlusion , bevacizumab , ranibizumab , central retinal vein occlusion , retrospective cohort study , corticosteroid , retinal , surgery , chemotherapy
Purpose To evaluate whether treatment with intravitreal corticosteroid and anti-vascular endothelial growth factor (VEGF) injections alternately can improve treatment outcomes of macular edema (ME) caused by retinal vein occlusion (RVO).Methods This dual-center retrospective study included 112 eyes with treatment-naïve ME secondary to RVO that were alternately treated with intravitreal corticosteroid and anti-VEGF injections (33 eyes, alternate group) or treated only with intravitreal anti-VEGF injections (79 eyes, anti-VEGF group) on a pro re nata basis.Results During the 12-month follow-up period, the alternate group achieved a visual acuity gain of 0.39 logMAR, while the anti-VEGF group achieved a gain of 0.21 logMAR ( P =0.042). The alternate group demonstrated a reduction in the central macular thickness of 229.9- μ m, while the anti-VEGF group achieved a reduction of 220.1 μ m ( P =0.887). The alternate group required an average of 5.2 injections, while the anti-VEGF received 4.2 injections ( P < 0.001). In a propensity score-matched cohort to compensate for the differences in the injection numbers between the two groups, the alternate group achieved a better visual acuity gain than the anti-VEGF group at month 12 (0.39 logMAR vs. 0.17 logMAR, P =0.048).Conclusions In ME secondary to RVO, treatment with intravitreal corticosteroid and anti-VEGF injections alternately resulted in a more favorable visual outcome compared with intravitreal anti-VEGF monotherapy.